← Human Trials & Peer-Reviewed Studies
Added value of cerebro-placental ratio and uterine artery Doppler at routine third trimester screening as a predictor of SGA and FGR in non-selected pregnancies.
Plain-language guide to PMID 29447050 (2019): clinical trial of Cerebrolysin.
Key Facts
- PMID
- 29447050
- Journal
- The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
- Year
- 2019
- Study type
- Clinical Trial
- Authors
- Rial-Crestelo M et al. (8 authors)
- DOI
- 10.1080/14767058.2018.1441281
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Cerebrolysin, published as a clinical trial.
The objective of this study is to determine the added value of cerebroplacental ratio (CPR) and uterine Doppler velocimetry at third trimester scan in an unselected obstetric population to predict smallness and growth restriction.
Who Took Part
By PubMed's age tags, the people studied were adults, women only.
The researchers constructed a prospective cohort study of women with singleton pregnancies attended for routine third trimester screening (32+0-34+6 weeks).
Both attending professionals and patients were blinded to the results, except in cases of estimated fetal weight < p10.
How the Study Was Run
Fetal biometry and fetal-maternal Doppler ultrasound examinations were performed by certified sonographers.
The CPR was calculated as a ratio of the middle cerebral artery to the umbilical artery pulsatility indices.
The association between third trimester Doppler parameters and small for gestational age (SGA) (birth weight <10th centile) and fetal growth restriction (FGR) (birth weight below the third centile) was assessed by logistic regression, where the basal comparison was a model comprising maternal characteristics and estimated fetal weight (EFW).
What Was Measured
Topics PubMed links to this paper include Fetal Growth Retardation, Infant, Small for Gestational Age, Middle Cerebral Artery, Ultrasonography, Prenatal, Umbilical Arteries and Uterine Artery.
Author keywords: Adverse perinatal outcome, Doppler assessment, cerebroplacental ratio, fetal growth restriction and third trimester screening.
What This Means in Plain Language
This is a clinical trial of Cerebrolysin.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2019 (The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians), a journal based in England.
More context: the Cerebrolysin compound page, all human trials.
Our Notes on the Compound
Cerebrolysin: A mixed neurotrophic preparation (NGF-, BDNF-, GDNF- and CNTF-like activity).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.